RE: Game Over in UK6 Jul 2021 23:00
Listening to the lunchtime Radio 4 news they were talking about school testing, again. They had a head teacher who said that: tests would have to be done at school so that the results could be believed; that: Primary kids couldn't test themselves and needed an adult to perform each test on the child; that: kids find it very uncomfortable to have their throats and upper noses swabbed, and make quick involuntary movements of the head – which would be dangerous with a swab far inside the nose.
The implication was that LFD testing of Primary kids was probably a non-starter.
This is what I immediately emailed to World At One. It could've been better written but should've done the job if they are listening:
''Hi World at One,
I mentioned this to you last week so that you could look into it. There is a new LFT that only needs to be inserted into the first part of the nostril. CE certified for pro use, the Avacta AffiDX test could unlock all schools as it’s really sensitive at detecting infectious people (even with a low viral load) rather than people with antibodies that would fail a PCR.
Kind regards,
Mr D-Geeman
Do please look at this:
07 Jun 2021
MHRA Confirms Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the MHRA has confirmed registration of Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test allowing the Company to place the product on the market in the UK for professional use.
Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others. The clinical data for Avacta’s AffiDX® SARS-CoV-2 antigen lateral flow test reported in April demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct<27.
Avacta has multiple ongoing commercial discussions with distributors and end user customers in countries that accept the CE mark for in vitrodiagnostic products. The product registration by the MHRA allows the Company to sell the product in the UK for professional use and the Company expects product registration from a Competent Authority within the EU to follow shortly.'